Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.67 |
| ▸ | NOS3 | P29474 | 5/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.55 |
| ▸ | HTR3B | O95264 | 2/20 | 0.55 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.55 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348627 | 1.00 | NOS1 (0.67) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL165971 | 1.00 | NOS1 (0.67) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL6650679 | 0.97 | NOS1 (0.64) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL7046514 | 0.92 | NOS1 (0.58) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL7051710 | 0.92 | NOS1 (0.58) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL3392567 | 0.90 | NOS1 (0.56) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL13726615 | 0.90 | NOS1 (0.56) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL7591503 | 0.90 | NOS1 (0.56) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL7592300 | 0.90 | NOS1 (0.56) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL13726617 | 0.90 | NOS1 (0.56) | NOS1NOS3HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363923-B1 | RHODIUM AND IRIDIUM COMPLEXES | MERCK PATENT GMBH (DE) | 2009-04-01 | — | — | EP | claimed |
| US-7125998-B2 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2006-10-24 | — | — | US | claimed |
| EP-1562964-B1 | PALLADIUM AND PLATINUM COMPLEXES | MERCK PATENT GMBH (DE) | 2006-07-19 | — | — | EP | claimed |
| EP-1562964-A1 | PALLADIUM AND PLATINUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2005-08-17 | — | — | EP | claimed |
| US-20040138455-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| WO-2004041835-A1 | PALLADIUM AND PLATINUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-05-21 | — | — | WO | claimed |
| EP-1363923-A1 | RHODIUM AND IRIDIUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2003-11-26 | — | — | EP | claimed |
| WO-2002068435-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2002-09-06 | — | — | WO | claimed |
| US-12635401-B2 | Metal complexes | UDC Ireland (IE) | 2026-05-19 | — | — | US | disclosed |
| EP-4069709-B1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-12250871-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2025-03-11 | — | — | US | disclosed |
| US-20240260448-A1 | Metal Complexes | UDC IRELAND LIMITED (IE) | 2024-08-01 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20230056324-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20040267057-A1 | Method for producing phenol condensate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-30 | — | — | US | disclosed |
| US-20040138455-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004041835-A1 | PALLADIUM AND PLATINUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037836-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
| EP-1363923-A1 | RHODIUM AND IRIDIUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002068435-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12635401-B2 | Metal complexes | SCO2, SOD1, NR4A1 | NOS1 1651/4885NOS3 1133/4885HTR3E 3745/4885 |
| US-20040138455-A1 | Rhodium and iridium complexes | RPIA, MPI, INPP5B | NOS1 3525/4885NOS3 3548/4885HTR3E 4057/4885 |
| US-12250871-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | NOS1 3933/4885NOS3 3351/4885HTR3E 3893/4885 |
| US-20230056324-A1 | METAL COMPLEXES | MCU, IMMT, SOD1 | NOS1 3890/4885NOS3 3227/4885HTR3E 4067/4885 |
| US-20040267057-A1 | Method for producing phenol condensate | SOD1, MLX, XDH | NOS1 1975/4885NOS3 1237/4885HTR3E 4296/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | NOS1 916/4885NOS3 1770/4885HTR3E 4627/4885 |
| US-20240260448-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | NOS1 3883/4885NOS3 3317/4885HTR3E 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.